Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,409 across all filing types
Latest filing 2015-09-17 Interim / Quarterly Rep…
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
Interim financial report
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim financial report June 30, 2015' and contains comprehensive interim consolidated financial statements, management discussion and analysis (MD&A), and notes for the six-month period. It is not a short announcement or a certification, but the full interim report itself, fitting the definition of an Interim/Quarterly Report (IR). H1 2015
2015-09-17 English
INNATE PHARMA: RESULTATS 1ER SEMESTRE 2015
Earnings Release Classification · 95% confidence The document is a press release from Innate Pharma dated September 17, 2015, announcing its financial results for the first half of 2015. It includes key financial highlights, a summary table of financial statements (IFRS), and detailed updates on clinical programs and corporate developments. While it contains financial data, it is structured as an earnings release (announcing results and providing a summary) rather than a full, audited interim report. Therefore, it is classified as an Earnings Release. H1 2015
2015-09-17 French
INNATE PHARMA: 1ST HALF 2015 RESULTS
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the first half of 2015 (H1 2015) for Innate Pharma. It includes detailed consolidated financial statements, balance sheets, income statements, and management commentary on R&D progress and corporate developments. Since it covers a period shorter than a full fiscal year and contains substantive financial data, it is classified as an Interim/Quarterly Report. H1 2015
2015-09-17 English
IPH 5eme DSMB EffiKIR
Regulatory Filings Classification · 89% confidence The document is a press release dated September 14, 2015, from Innate Pharma SA. It announces that the Data and Safety Monitoring Board (DSMB) recommended continuing the EffiKIR clinical trial without modification. The text details the status of a Phase II clinical trial (EffiKIR) involving lirilumab for Acute Myeloid Leukemia (AML), mentions partnership details (Bristol-Myers Squibb), and provides company background and forward-looking statements/disclaimers typical of corporate news releases regarding clinical progress. This type of announcement, focusing on clinical trial updates, safety monitoring board decisions, and pipeline progress, is best classified as an Investor Presentation (IP) if it were a deck, or more generally, a specific type of corporate update. However, none of the codes perfectly match 'Clinical Trial Update'. Given the content focuses heavily on the scientific rationale, trial design, and partnership structure, it functions as detailed information provided to investors about the company's core assets. Since it is not a formal financial report (10-K, IR, ER, MRQ), nor a management discussion (MDA), nor a general regulatory filing (RNS), and it is more detailed than a simple Earnings Release (ER), the closest fit among the provided options that covers detailed operational/scientific updates aimed at investors is Investor Presentation (IP), as these often include detailed pipeline updates, even if presented as a press release rather than a slide deck. Alternatively, it could be seen as a Regulatory Filing (RNS) if no better fit exists, but IP captures the nature of the detailed scientific/pipeline update better than the general RNS fallback.
2015-09-14 French
IPH fifth DSMB EffiKIR
Regulatory Filings Classification · 92% confidence The document is a press release dated September 14, 2015, announcing the outcome of the 'fifth Data and Safety Monitoring Board Meeting of the EffiKIR Trial,' which recommended continuation without modification. This type of announcement, detailing the progress or status of a clinical trial based on independent review, does not fit neatly into standard financial reporting categories like 10-K, ER, or IR. It is a specific update related to ongoing operations and research. Since it is not a formal financial report, a management discussion, a proxy statement, or a standard regulatory filing (like a major shareholding change or director dealing), it falls best under the general 'Regulatory Filings' (RNS) category as a specific operational/clinical update released to the public, or potentially a specialized 'LTR' if the trial itself was regulatory-driven, but RNS serves as the best general announcement fallback for non-standard corporate news.
2015-09-14 English
150907 IPH Upcoming investor conferences
Report Publication Announcement Classification · 98% confidence The document is a press release dated September 7, 2015, announcing the company's schedule for upcoming investor conferences and, crucially, stating that the company "will publish its half-year results on September 17, 2015 before French market opens." It also mentions that a conference call will take place on the same day. This document is not the actual half-year financial report (which would be an IR) nor is it the transcript of the call (CT). Instead, it is an announcement about the future publication of results and related events. Since it announces the release of a report, it fits the definition of a Report Publication Announcement (RPA). The document length (4310 chars) is relatively short for a full financial report, supporting the RPA classification based on the 'MENU VS MEAL' rule.
2015-09-07 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.